The Corporation focussed on the biology of healing recently reported full year results for FY December 2016. Net losses doubled to $110.7m, but within that were R&D expenses of $88.1m. We have drilled down into how ProMetic has been allocating its investment and seen that it is building a portfolio of valuable licensed drugs, the first of which is due to launch this year. Given the breadth of the pipeline there should be options to commercialise several candidates either in their own righ
05 Apr 2017
Shaping up to become a conveyor belt of high value therapeutics
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shaping up to become a conveyor belt of high value therapeutics
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
05 Apr 2017 -
Author:
Derren Nathan -
Pages:
7
The Corporation focussed on the biology of healing recently reported full year results for FY December 2016. Net losses doubled to $110.7m, but within that were R&D expenses of $88.1m. We have drilled down into how ProMetic has been allocating its investment and seen that it is building a portfolio of valuable licensed drugs, the first of which is due to launch this year. Given the breadth of the pipeline there should be options to commercialise several candidates either in their own righ